ArticleThe Lancet regional health. Europe2022
Omicron SARS-CoV-2 epidemic in England during February 2022: A series of cross-sectional community surveys.
Article in The Lancet regional health. Europe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.Human vaccines & immunotherapeutics · 2023Pooled it
- Phenotypic Evolution, Clinical Subtypes, and Independent Predictors of Long COVID: A Retrospective Cohort Study.Biomedicines · 2026Article
- What is the connection between screen time and lifestyle factors important for bone health? Findings from the Hertfordshire Intergenerational Study.Archives of osteoporosis · 2026Article
- Health inequalities in risk of SARS-CoV-2 infection in England's second wave: population-based cross-sectional analysis from the REACT-1 study.BMJ public health · 2026Article
- Inferring temporal trends of multiple pathogens, variants, subtypes or serotypes from routine surveillance data.American journal of epidemiology · 2025Article
- SARS-CoV-2 dynamics in New York City during March 2020-August 2023.Communications medicine · 2025Article
- Outpatient pediatric care during the COVID-19 pandemic, Almaty, Kazakhstan 2021-2022.Frontiers in public health · 2025Article
- Biases in Routine Influenza Surveillance Indicators Used to Monitor Infection Incidence and Recommendations for Improvement.Influenza and other respiratory viruses · 2024Article
- Challenges in the case-based surveillance of infectious diseases.Royal Society open science · 2024Article
- A large-scale and PCR-referenced vocal audio dataset for COVID-19.Scientific data · 2024Article
- Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.Annals of hematology · 2023Article
- Genomic assessment of invasion dynamics of SARS-CoV-2 Omicron BA.1.Science (New York, N.Y.) · 2023Article
- Design and Implementation of a National SARS-CoV-2 Monitoring Program in England: REACT-1 Study.American journal of public health · 2023Article
- BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies.PLoS pathogens · 2023Article
- The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.Journal of medical virology · 2023Review
- Dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 in England.Nature communications · 2022Article
- Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England.Science (New York, N.Y.) · 2022Article
- Estimating disease severity of Omicron and Delta SARS-CoV-2 infections.Nature reviews. Immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 2 countries.
Funding
Abstract
Background: The Omicron wave of COVID-19 in England peaked in January 2022 resulting from the rapid transmission of the Omicron BA.1 variant. We investigate the spread and dynamics of the SARS-CoV-2 epidemic in the population of England during February 2022, by region, age and main SARS-CoV-2 sub-lineage. Methods: In the REal-time Assessment of Community Transmission-1 (REACT-1) study we obtained data from a random sample of 94,950 participants with valid throat and nose swab results by RT-PCR during round 18 (8 February to 1 March 2022). Findings: We estimated a weighted mean SARS-CoV-2 prevalence of 2.88% (95% credible interval [CrI] 2.76-3.00), with a within-round effective reproduction number (R) overall of 0.94 (0·91-0.96). While within-round weighted prevalence fell among children (aged 5 to 17 years) and adults aged 18 to 54 years, we observed a level or increasing weighted prevalence among those aged 55 years and older with an R of 1.04 (1.00-1.09). Among 1,616 positive samples with sublineages determined, one (0.1% [0.0-0.3]) corresponded to XE BA.1/BA.2 recombinant and the remainder were Omicron: Interpretation: In February 2022, infection prevalence in England remained high with level or increasing rates of infection in older people and an uptick in hospitalisations. Ongoing surveillance of both survey and hospitalisations data is required. Funding: Department of Health and Social Care, England.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.